



# Pharmaids Pharmaceuticals Limited

Date: 23.07.2021

To,  
BSE LIMITED,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Fort Mumbai-400 001

Dear Sir / Madam,

**BSE Script Code: 524572**

**Subject: Outcome of Board Meeting – Jul 23, 2021**

In Continuation to our intimation dated July 16, 2021 regarding the Board Meeting Notice, we would like to inform you that the Board of Directors (the “**Board**”) of **PHARMAIDS PHARMACEUTICALS LIMITED** (the “**Company**”) at its meeting held today i.e. Friday, July 23, 2021 has considered and approved the Un-Audited Financial Results along with the Auditors Limited Review Report for the Quarter ended June 30, 2021 Pursuant to regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulation’) which has been duly reviewed and recommended by the Audit Committee.

We are enclosing herewith the audited financial results along with Audit Report signed by our Statutory Auditors, M/s. PPKG & Co, Chartered Accountants.

The Board Meeting Commenced at 2.30 PM and concluded at 4.00 PM.

Please take note of the same on your record.

Thanking You,

Yours faithfully

For **Pharmaids Pharmaceuticals Limited**

*Padma*

S. Padmaja Kalyani  
Director (DIN: 03096445)





# Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited

Statement of Unaudited Financial Results for the quarter ended 30 June 2021				
Particulars	Rupees in lakhs			
	Quarter ended		Year ended	
	30/06/2021	31/03/2021	30/06/2020	31/03/2021
	Unaudited (Reviewed)	Audited	Unaudited (Reviewed)	Audited
Income				
Revenue from Operations	234.16	188.52	0.00	855.10
Other Income	0.00	0.00	2.63	2.63
<b>Total Income</b>	<b>234.16</b>	<b>188.52</b>	<b>2.63</b>	<b>857.73</b>
Expenses				
Cost of Material Consumed	0.00	0.00	0.00	0.00
Purchase of Stock in Trade	242.90	78.52	0.00	852.82
Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade	(20.85)	90.73	0.00	(36.91)
Employee benefit expenses	1.77	2.36	0.30	4.43
Finance Cost	0.00		0.00	
Depreciation and amortisation expense	0.38	1.12	1.11	4.48
Other expenses	5.73	14.06	0.88	24.07
<b>Total expenses</b>	<b>229.93</b>	<b>186.79</b>	<b>2.29</b>	<b>848.89</b>
Profit/ (loss) before exceptional items and tax	4.22	1.73	0.34	8.84
Exceptional items	0.00	0.00	0.00	0.00
<b>Profit/ (loss) before tax</b>	<b>4.22</b>	<b>1.73</b>	<b>0.34</b>	<b>8.84</b>
Tax expenses:				
(1) Current Tax	0.00	(2.08)	0.00	0.00
(2) Deferred Tax	3.21	(0.49)	0.00	(0.49)
Profit/ (loss) for the period from continuing operations	<b>1.01</b>	<b>4.30</b>	<b>0.34</b>	<b>9.33</b>
Profit/ (loss) from discontinued operations	0.00	0.00	0.00	0.00
Tax expense of discontinued operations	0.00	0.00	0.00	0.00
Profit/ (loss) from discounting operations (after tax)	0.00	0.00	0.00	0.00
<b>Profit/ (loss) for the period</b>	<b>1.01</b>	<b>4.30</b>	<b>0.34</b>	<b>9.33</b>
Other comprehensive income	0.00	0.00	0.00	0.00
Total comprehensive income for the period (Profit/ loss + other comprehensive income)	0.00	0.00	0.00	0.00
<b>Earnings per equity share (for continuing operations)</b>				
a) Basic	0.01	0.04	0.00	0.09
b) Diluted	0.01	0.04	0.00	0.09
<b>Earnings per equity share (for discontinued operations)</b>				
a) Basic	0.00	0.00	0.00	0.00
b) Diluted	0.00	0.00	0.00	0.00
<b>Earnings per equity share (for discontinued &amp; continuing operations)</b>				
a) Basic	0.01	0.04	0.00	0.09
b) Diluted	0.01	0.04	0.00	0.09

1. The above results were approved at the meeting of the Board of Directors held on July 23, 2021. 2. The Company operates in a single segment. 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. During this pandemic, business operations and financial position has revealed that there has been no significant impact on company's financial results as on 30th June 2021. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as on the date of approval of these financial results. The Company will continue to monitor such impact in future economic conditions.

Place : Hyderabad  
Date : 23-07-2021

By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited

*Padma*  
S. Padmaja Kalyani  
Director



Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : pharmaids125@gmail.com , Web : www.pharmaids.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON  
REVIEW OF INTERIM FINANCIAL RESULTS**

To  
The Board of Directors,  
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited Financial Results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the Quarter Ended 30<sup>th</sup> June, 2021 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place:** Hyderabad

**Date:** 23<sup>rd</sup> July, 2021

**UDIN:** 21205140AAAAJE9746

**For PPKG & CO**  
Chartered Accountants  
FRN No. 009655S

*Girdhari Lal Toshniwal*

A circular blue ink stamp for PPKG & CO Chartered Accountants. The text 'PPKG & CO' is at the top, 'Chartered Accountants' is at the bottom, and there are two stars on either side of the bottom text. A signature in blue ink is written across the stamp.

**GIRDHARI LAL TOSHNIWAL**  
(Partner)  
M. No. 205140